Dean Y. Maeda

3.0k total citations · 1 hit paper
35 papers, 1.8k citations indexed

About

Dean Y. Maeda is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Dean Y. Maeda has authored 35 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Molecular Biology and 12 papers in Immunology. Recurrent topics in Dean Y. Maeda's work include Cancer Immunotherapy and Biomarkers (9 papers), Chemokine receptors and signaling (7 papers) and Immune cells in cancer (6 papers). Dean Y. Maeda is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Chemokine receptors and signaling (7 papers) and Immune cells in cancer (6 papers). Dean Y. Maeda collaborates with scholars based in United States, Netherlands and Austria. Dean Y. Maeda's co-authors include John A. Zebala, Andrew Coop, Lucas A. Horn, Claudia Palena, Jeffrey Schlom, Sarah Greene, Yvette Robbins, Paúl E. Clavijo, Jay Friedman and Clint Allen and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Dean Y. Maeda

34 papers receiving 1.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effective combinatorial immunotherapy for castration-resistant prostate cancer

2017 396 citations John A. Zebala, Dean Y. Maeda et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dean Y. Maeda United States	16	846	781	472	218	217	35	1.8k
Hassan Salari Canada	21	351 0.4×	411 0.5×	508 1.1×	293 1.3×	123 0.6×	51	1.6k
Yih‐Fung Chen Taiwan	23	261 0.3×	232 0.3×	1.0k 2.2×	173 0.8×	212 1.0×	50	1.8k
Le Yu China	25	357 0.4×	136 0.2×	932 2.0×	98 0.4×	152 0.7×	57	1.7k
Gary Elliott United States	19	366 0.4×	298 0.4×	493 1.0×	55 0.3×	84 0.4×	52	1.6k
Zhiwen Fu China	15	699 0.8×	166 0.2×	591 1.3×	155 0.7×	43 0.2×	45	1.5k
Edward F. Webb United States	20	267 0.3×	341 0.4×	778 1.6×	233 1.1×	205 0.9×	36	1.7k
Mariana S. De Lorenzo United States	19	329 0.4×	255 0.3×	548 1.2×	98 0.4×	67 0.3×	36	1.3k
Réjean Ruel Canada	19	310 0.4×	315 0.4×	1.4k 3.0×	111 0.5×	131 0.6×	32	2.4k
Chia‐Ron Yang Taiwan	25	316 0.4×	263 0.3×	1.0k 2.2×	92 0.4×	72 0.3×	56	1.7k
Yoonha Hwang United States	17	334 0.4×	220 0.3×	945 2.0×	79 0.4×	544 2.5×	31	1.5k

Countries citing papers authored by Dean Y. Maeda

Since Specialization

Citations

This map shows the geographic impact of Dean Y. Maeda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dean Y. Maeda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dean Y. Maeda more than expected).

Fields of papers citing papers by Dean Y. Maeda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dean Y. Maeda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dean Y. Maeda. The network helps show where Dean Y. Maeda may publish in the future.

Co-authorship network of co-authors of Dean Y. Maeda

This figure shows the co-authorship network connecting the top 25 collaborators of Dean Y. Maeda. A scholar is included among the top collaborators of Dean Y. Maeda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dean Y. Maeda. Dean Y. Maeda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Jinming, Weifeng Luo, Patricia A. Ward, et al.. (2025). Combined treatment with CDK4/6, CDK2, and CXCR1/2 inhibitors effectively halts the growth of BRAF wild-type melanoma tumors. Frontiers in Oncology. 15. 1609735–1609735.

Patel, Sapna P., Anastasios Dimou, Adrienne I. Victor, et al.. (2024). Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.. Journal of Clinical Oncology. 42(16_suppl). 9508–9508. 10 indexed citations

Horn, Lucas A., Hanne Lind, Kristen Fousek, et al.. (2024). Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer models. Journal of Experimental & Clinical Cancer Research. 43(1). 318–318. 4 indexed citations

Zebala, John A., et al.. (2023). Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies. Cancers. 15(8). 2366–2366. 9 indexed citations

Sallman, David A., Amy E. DeZern, Arlene A. Gayle, et al.. (2022). Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes. Blood. 140(Supplement 1). 2070–2072. 11 indexed citations

Zebala, John A., Aaron D. Schuler, Stuart J. Kahn, & Dean Y. Maeda. (2020). Desmetramadol Is Identified as a G-Protein Biased µ Opioid Receptor Agonist. Frontiers in Pharmacology. 10. 1680–1680. 12 indexed citations

Greene, Sarah, Yvette Robbins, Wojciech K. Mydlarz, et al.. (2019). Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clinical Cancer Research. 26(6). 1420–1431. 217 indexed citations

Kargl, Julia, Xiaodong Zhu, Huajia Zhang, et al.. (2019). Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight. 4(24). 127 indexed citations

Zebala, John A., et al.. (2019). Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. Journal of Pain. 20(10). 1218–1235. 9 indexed citations

10.

Sun, Lillian, Paúl E. Clavijo, Yvette Robbins, et al.. (2019). Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 4(7). 188 indexed citations

11.

Maeda, Dean Y., Aaron D. Schuler, Mark T. Quinn, et al.. (2015). Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model. Bioorganic & Medicinal Chemistry Letters. 25(11). 2280–2284. 12 indexed citations

12.

Menter, Alan, Christina Cherian, Larry H. Matherly, et al.. (2012). Intestinal Transport of Aminopterin Enantiomers in Dogs and Humans with Psoriasis Is Stereoselective: Evidence for a Mechanism Involving the Proton-Coupled Folate Transporter. Journal of Pharmacology and Experimental Therapeutics. 342(3). 696–708. 15 indexed citations

13.

Maeda, Dean Y., Mark T. Quinn, Igor A. Schepetkin, Liliya N. Kirpotina, & John A. Zebala. (2009). Nicotinamide Glycolates Antagonize CXCR2 Activity through an Intracellular Mechanism. Journal of Pharmacology and Experimental Therapeutics. 332(1). 145–152. 9 indexed citations

14.

Kallapur, Suhas G., Timothy J. M. Moss, Richard L. Auten, et al.. (2009). IL-8 signaling does not mediate intra-amniotic LPS-induced inflammation and maturation in preterm fetal lamb lung. American Journal of Physiology-Lung Cellular and Molecular Physiology. 297(3). L512–L519. 27 indexed citations

15.

Maeda, Dean Y., Sumit Mahajan, William M. Atkins, & John A. Zebala. (2006). Bivalent inhibitors of glutathione S-transferase: The effect of spacer length on isozyme selectivity. Bioorganic & Medicinal Chemistry Letters. 16(14). 3780–3783. 21 indexed citations

16.

Lentz, Kimberley A., et al.. (2003). Increased Acyclovir Oral Bioavailability via a Bile Acid Conjugate. Molecular Pharmaceutics. 1(1). 40–48. 102 indexed citations

17.

Maeda, Dean Y., et al.. (2002). N-Arylalkylpiperidines as High-Affinity Sigma-1 and Sigma-2 Receptor Ligands: Phenylpropylamines as Potential Leads for Selective Sigma-2 Agents. Bioorganic & Medicinal Chemistry Letters. 12(3). 497–500. 31 indexed citations

18.

Huang, Susan M., Tiziana Bisogno, Timothy J. Petros, et al.. (2001). Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain. Journal of Biological Chemistry. 276(46). 42639–42644. 261 indexed citations

19.

Maeda, Dean Y., Jane E. Ishmael, Thomas F. Murray, & Jane V. Aldrich. (2000). Synthesis and Evaluation ofN,N-Dialkyl Enkephalin-Based Affinity Labels for δ Opioid Receptors. Journal of Medicinal Chemistry. 43(21). 3941–3948. 12 indexed citations

20.

Maeda, Dean Y., et al.. (2000). A sigma-1 receptor selective analogue of BD1008. a potential substitute for (+)-opioids in sigma receptor binding assays. Bioorganic & Medicinal Chemistry Letters. 10(1). 17–18. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact